The British-Swedish drugmaker AstraZeneca published positive Phase 3 results Friday for tozorakimab, an anti-IL-33 antibody, in chronic obstructive pulmonary disease — and the interesting part is not the win. It is the comeback story.
Nearly 400 million people are diagnosed with COPD, a progressive lung disease and the third leading cause of death globally, according to the company filing. Even on standard inhaled therapy, more than half still experience acute exacerbations — flare-ups that accelerate lung decline, spike hospitalization risk, and can be fatal. That persistent unmet need is why every major respiratory biologic maker is crowded into this space. AstraZeneca wants to be next.
Tozorakimab is a monoclonal antibody that blocks interleukin-33, a cytokine high in the inflammatory cascade that drives COPD exacerbations. In the OBERON and TITANIA Phase 3 trials, tozorakimab reduced the annualized rate of moderate-to-severe exacerbations compared with placebo, in both the primary population of former smokers and the broader overall population that included current smokers and patients regardless of blood eosinophil count, according to the company announcement. A total of 2,306 patients were randomized across both trials. Dosing was 300 milligrams or placebo added to standard care once every four weeks over 52 weeks. AstraZeneca called it the first IL-33-targeting biologic to demonstrate statistically significant COPD exacerbation reductions in two replicate Phase 3 trials.
The mechanism is worth pausing on. Dupilumab, Regeneron Pharmaceuticals IL-4/13 inhibitor approved for COPD in September 2024, targets cytokines further downstream in the same inflammatory pathway. Tezepelumab, AstraZeneca and Amgens anti-TSLP antibody, is approved for severe asthma and received FDA breakthrough therapy designation for COPD in July 2024. Tozorakimab, meanwhile, received FDA Fast Track designation for COPD in December 2024 — a different FDA program with different implications. The two drugs are not on equivalent regulatory tracks, though both are chasing the same COPD biologic market. Tozorakimabs claim — that inhibiting IL-33 covers more COPD patients across more inflammatory phenotypes — has to be read against that competitive backdrop. IL-33 is released in response to airway epithelial injury from tobacco smoke and other irritants, making it a proximal alarm node in the inflammatory cascade, the company noted in its announcement, arguing that upstream blockade gives tozorakimab its breadth.
That argument is also the story of the drugs journey from Phase 2 to Phase 3. Tozorakimab's earlier COPD trial in an unselected population — part of the LUNA programme led by Frank Sciurba — did not demonstrate sufficient efficacy to advance on its own. Like nearly every respiratory biologic before it, the signal emerged when AZ tightened the inclusion criteria to former smokers with two or more prior exacerbations, a standard enrichment strategy to find a cleaner Type 2 inflammatory signal. The Phase 3 trials OBERON and TITANIA ran with that enriched design.
But OBERON and TITANIA went further. Rather than restricting to high-eosinophil patients — the typical COPD biologic enrollment strategy — AstraZeneca enrolled across all eosinophil counts and lung function severity stages. The company characterized the results in the broader population as a win, not just a former-smoker win. Whether the current smoker and low-eosinophil data represents a pre-specified co-primary analysis or a key secondary varies by trial arm, and the magnitude of exacerbation reduction across subgroups has not been disclosed. Frank Sciurba, a professor of pulmonary and critical care medicine at the University of Pittsburgh who led the earlier LUNA program of Phase 2 tozorakimab studies, did not respond to a request for comment before publication.
Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, said in the company announcement that the results support the potential of tozorakimab to address the significant unmet need in COPD, where more than 50 percent of patients on available therapies continue to experience exacerbations. She characterized the broader population results as validating the IL-33 pathway as a key driver of COPD inflammation across multiple phenotypes.
The caveat is structural. Two additional Phase 3 trials, PROSPERO and MIRANDA, are still enrolling, with results expected in the first half of 2026. Those trials should sharpen the current-smoker and low-eosinophil pictures. Without the absolute exacerbation reduction numbers — AstraZeneca has not disclosed magnitude in the announcement — it is difficult to assess how clinically meaningful the effect size is relative to Dupixents published COPD data or the anti-TSLP results from tezepelumab.
The competitive question matters beyond the biology. Dupixent is well-established in COPD with a large real-world evidence base. Tezpire is newer and still building its clinical record. Tozorakimab, if approved, enters a market where pulmonologists are already familiar with biologic therapy in COPD — a shift that took a decade to establish. The more salient question for builders and investors is whether the IL-33 mechanism finds a distinct patient population that the downstream drugs do not reach, or whether the COPD biologic market is large enough that all three mechanisms coexist.
What to watch next: PROSPERO and MIRANDA data in H1 2026 will determine whether tozorakimabs breadth claim holds up in the patients most excluded from current biologics — current smokers and those with low eosinophil counts. If those results match the OBERON/TITANIA signal, the IL-33 story gets significantly more interesting. If they do not, the Phase 3 vindication was really an enrichment story all along.
